Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598513 | 0.88 | CDK2 (0.45) | CSNK1DNTRK1CDK2 | |
| SCHEMBL3585775 | 0.83 | CDK1 (0.54) | CSNK1DNTRK1CCNT1CCNE1CDK2 | |
| SCHEMBL3589570 | 0.79 | CSNK1D (0.41) | CSNK1DNPC1CCNT1CCNE1CDK2 | |
| SCHEMBL4439037 | 0.79 | CSNK1D (0.43) | CSNK1DNPC1CDK2 | |
| SCHEMBL3587372 | 0.79 | CSNK1D (0.41) | CSNK1DNPC1RAB9A | |
| SCHEMBL1590850 | 0.76 | HPGD (0.46) | GRM5HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3600080 | 0.75 | CSNK1D (0.41) | CSNK1DNPC1ALDH1A1RAB9AMEN1 | |
| SCHEMBL3586487 | 0.73 | ABL1 (0.39) | CSNK1DNPC1 | |
| SCHEMBL1590863 | 0.72 | NPC1 (0.50) | GRM5HPGDNPC1ALDH1A1CDK2 | |
| SCHEMBL12727080 | 0.71 | PDGFRA (0.58) | CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | claimed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | claimed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | claimed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | GRM5 1751/4885CSNK1D 1542/4885HPGD 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.